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Abstract
Perlecan Domain V (DV) promotes brain angiogenesis by inducing VEGF release from brain endothelial cells (BECs) following
stroke. In this study, we define the specific mechanism of DV interaction with the a5b1 integrin, identify the downstream
signal transduction pathway, and further investigate the functional significance of resultant VEGF release. Interestingly, we
found that the LG3 portion of DV, which has been suggested to possess most of DV’s angio-modulatory activity outside of
the brain, binds poorly to a5b1 and induces less BEC proliferation compared to full length DV. Additionally, we implicate
DV’s DGR sequence as an important element for the interaction of DV with a5b1. Furthermore, we investigated the
importance of AKT and ERK signaling in DV-induced VEGF expression and secretion. We show that DV increases the
phosphorylation of ERK, which leads to subsequent activation and stabilization of eIF4E and HIF-1a. Inhibition of ERK activity
by U0126 suppressed DV-induced expression and secretion of VEGR in BECs. While DV was capable of phosphorylating AKT
we show that AKT phosphorylation does not play a role in DV’s induction of VEGF expression or secretion using two
separate inhibitors, LY294002 and Akt IV. Lastly, we demonstrate that VEGF activity is critical for DV increases in BEC
proliferation, as well as angiogenesis in a BEC-neuronal co-culture system. Collectively, our findings expand our
understanding of DV’s mechanism of action on BECs, and further support its potential as a novel stroke therapy.
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Introduction
Stroke is the leading cause of long term disability and a major
cause of death within the United States, with an average fatality
rate slightly over 134,000 deaths/year and an overall cost of over
$7 billion/year [1]. A better understanding of the mechanisms
underlying brain self-repair after stroke constitutes an essential
research priority [2] and could lead to improving brain reparative
processes. Following cerebral ischemia, there is rapid proteolysis of
the extracellular matrix (ECM) as well as dramatic changes in the
expression of ECM receptors, cell-bound integrins, in the infarct
core and ischemic penumbra regions [3–5]. Within this context,
we hypothesized that the brain ECM may play a role in post-
stroke brain repair.
Several ECM components have C-terminal fragments that
possess biological activity following proteolytic cleavage from their
parent protein [6,7]. Perlecan, an ECM heparan sulfate proteo-
glycan, contains 5 distinct protein domains (Domains I-V), each
containing protein subunits with structural homology to other
proteins [8]. Domain V (DV), the C-terminal fragment of
perlecan, has anti-angiogenic activity outside of the brain following
cleavage from perlecan, and therefore is also referred to as
endorepellin [9,10]. DV is an 82 kDa peptide composed of three
laminin-like globular (LG1, 2, and 3) subunits, each separated by
two epidermal growth factor (EGF, termed EGF1–4 from N
terminus to C terminus) subunits. Importantly, LG3, the 24 kDa
C-terminal portion of DV, has been reported to be responsible for
DV’s anti-angiogenic activity [11].
Until recently, the only DV/LG3 receptor described in
endothelial cells was the collagen receptor a2b1 integrin [12].
Interestingly, although equal or significantly lower nanomolar
concentrations of LG3 (compared to DV) are required for a2b1
integrin-mediated suppression of angiogenesis, LG3 binds to the
a2b1 integrin (specifically, the a2 ligand binding domain) with
significantly lower affinity (Kd of 1 mM) than does full length DV
(Kd of 80 nM), suggesting a much more complex relationship
between DV, its LG3 component, the a2b1 integrin, and inhibition
of angiogenesis [11]. Indeed, a more complex relationship has
been suggested whereby the LG1 and LG2 components of intact
DV bind to VEGFR1 or VEGFR2 and the LG3 portion
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simultaneously binds to a2b1 resulting in transcriptional repression
of VEGF [13].
It has been shown that DV and LG3 are actively and
persistently cleaved from full length perlecan after stroke [14,15]
by a number of proteases including BMP-1/Tolloid-like metallo-
proteases and cathepsin-L [16,17]. We recently demonstrated that
DV is unexpectedly pro-angiogenic both in vitro and in vivo after
experimental focal cerebral ischemia [14]. This pro-angiogenic
effect occurs in brain microvessels, where the a2b1 integrin is
largely absent [18,19], and is instead driven by VEGF released
following direct interaction of DV with the fibronectin receptor
a5b1 integrin. However, the mechanisms by which DV interacts
with a5b1 and induces VEGF expression, as well as the potential of
LG3 to bind a5b1 and/or exert a pro-angiogenic effect in brain
endothelial cells (BECs), remain unclear. Therefore, the present
study aimed to: 1) Further define the interaction of DV with the
a5b1 integrin, 2) Evaluate LG3 binding to a5b1 integrin and
determine whether it also exerts pro-angiogenic activity on BECs,
3) Identify the signaling pathways activated downstream of DV’s
interaction with the a5b1 integrin that results in VEGF release,
and 4) Further demonstrate the functional significance of DV’s
induction of VEGF on BEC cell physiology. Collectively, our
findings expand our understanding of DV’s mechanism of action
on BECs, and further support its potential as a novel stroke
therapy.
Results
DV Binding to a5b1 Integrin is Partially Mediated by its
DGR Sequence
DV binds to the a5b1 integrin with a Kd of 160 nM [14]. One
possibility for how this interaction might occur is that human DV
contains a single DGR amino acid sequence (amino acid number
3904–3906) within its second EGF-like repeat (EGF2) immediately
before LG2 [20,21]. DGR sequences are known to bind integrins
and spontaneous, non-enzymatic isomerization by dehydration of
the aspartic acid (D) to iso-D, results in a novel iso-DGR integrin
binding motif for a5b1 and avb3 integrins [22,23]. In order to
determine the importance of DV’s DGR sequence for DV’s
interaction with a5b1 integrin, as well as its importance for DV’s
proangiogenic activity, we generated a DV mutant that has an ‘A’
in the place of the ‘D’ in the DGR sequence (D3904A DV,
Figure 1A). D3904A DV did not deleteriously effect protein
purification (Figure 1B). Optical biosensor analysis demonstrated
that D3904A DV bound to a5b1 integrin with significantly lower
affinity than wild-type DV, as we measured a Kd of
3.76102763.561029 M, Kon of 6.0610
564.56104/M-s and Koff
of 2.26102161.961022/s (as compared to Kd of
1.66102767.261028 M, Kon of 3.8610
662.76105/M-s, and Koff
of 7.26102161.161021/s for wild-type DV [14]) (Figure 1C).
Because we observed a significant difference in our Kd values of
WT DV and D3904A DV, we next asked whether this mutation
had any functional significance in our proliferation assays.
The decrease in affinity was accompanied by lower BEC
proliferative activity of D3904A DV compared to wild-type DV
(Figure 1D). We should note; however, that although we observed
this lower proliferative affect at 100 nM (*P,0.05), no difference
was observed at higher concentrations between wild-type DV and
D3904A DV, suggesting we had reached saturating concentrations
of WT DV and D3904A DV.
Next, as previous work had demonstrated that LG3 had
significantly less affinity for the a2 integrin compared to WT DV
[11], we were interested in determining whether this was also the
case for LG3’s affinity for a5b1 integrin, and what effect, if any, it
had of BEC proliferation compared to WT DV. Biosensor analysis
demonstrated that LG3 bound with a much lower affinity
(compared to WT DV) to a5b1 integrin with a measured Kd of
only 1.06102367.061025 M, a Kon of 1.6610
365.86101/M-s,
and a Koff of 1.764.3610
22/s (Figure 1E). Furthermore, LG3 was
less proliferative in BEC compared to wild-type DV (Figure 1F).
Indeed, LG3 concentrations as high as 1200 nM were still less
effective than 300 nM DV in stimulating BEC proliferation.
Additionally, unlike WT DV, LG3 did not elicit a proliferative
dose response in BECs.
DV Induces Akt Phosphorylation through a PI3K-
dependent Mechanism
To investigate the intracellular signaling cascade involved with
DV-induced VEGF release [14], we investigated the temporal
phosphorylation of several cell signal transduction components
known to be involved in VEGF regulation, such as Akt and ERK
[24], and whether inhibition of these components could inhibit
DV-induced VEGF release.
Treatment of BECs with DV resulted in a significant increase
in Akt phosphorylation (pAkt) at both 5 and 30 min as
measured by western blot (**P,0.01 and *P,0.05 respectively,
Figure 2A). (It should be noted, however, that under some
circumstances elevated basal pAkt was unavoidable). Because we
observed elevated basal pAkt in some scenarios, we performed a
cell-based ELISA and confirmed DV induces p-Akt (data not
shown). In the presence of 10 mM LY294002, a selective PI3K
inhibitor, we observed a significant delay in DV-induced Akt
phosphorylation, resulting in a significant increase in pAKT
only at 30 min. We further investigated decreased activation in
Akt phosphorylation in the presence of 10 mM Akt IV, another
inhibitor of Akt activity (Figure 2B). Akt IV blocks the ATP
binding site of a kinase upstream to AKT yet downstream to
PI3K. In the presence of Akt IV, basal pAkt levels were
increased compared to the untreated group. However, addition
of DV to BECs in the presence of Akt IV did not cause any
change in pAkt at 5 or 30 min.
Akt Inhibition by Pharmacological Agents Prevents DV-
induced ERK Phosphorylation
PI3K/Akt and MEK-ERK signaling pathways have previ-
ously been shown to cross-talk [25]. Therefore, we investigated
the impact of Akt phosphorylation on ERK phosphorylation,
following DV exposure, by investigating changes in phosphor-
ylated ERK levels in the presence of LY294002 or Akt IV
(Figure 2C, D). In the absence of these inhibitors, DV rapidly
induced ERK phosphorylation compared to basal levels. In the
presence of 10 mM LY294002 there was an increase in
phosphorylated ERK (pERK), suggesting that basal PI3K/Akt
activity may partially inhibit the ERK signaling pathway [24].
In the presence of LY294002, the addition of DV did not
induce any further increases in pERK levels at 5 min, yet at
30 min, we observed a significant decrease in pERK. As
observed with LY294002, Akt IV increased pERK levels under
basal conditions (Figure 2D). Although we observed a slight
decrease in pERK levels at 5 min, pERK levels rose above
baseline at 30 min.
DV Induction of VEGF Gene Expression and Secretion is
Driven through a ERK1/2 Dependent Pathway
BDNF-induced activation of PI3K/AKT and MEK pathways
in endothelial cells leads to the induction of VEGF secretion.
Therefore, because DV induces VEGF expression and secretion in
Mechanism of VEGF Section in BECs via Perlecan DV
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BECs and also activates Akt and ERK, we next investigated
whether DV-inducted VEGF expression and secretion could be
mediated by or involve Akt and ERK activation. Quantitative
PCR was used to detect VEGF-A expression with and without DV
treatment (1.5 h), in the absence or presence of Akt or ERK
inhibitors. LY294002 or Akt IV alone increased VEGF-A mRNA
basal levels. To our surprise, neither inhibitor was efficient in
blocking DV-induced VEGF-A mRNA up-regulation (Figure 3A).
Instead, we observed a significant increase in VEGF mRNA
expression when cells were treated with both DV and either
inhibitor. However, U0126 (10 mM) was able to significantly
inhibit DV-induced VEGF-A mRNA expression (Figure 3B).
Next, VEGF-A ELISA was performed to detect secreted VEGF-A
from BECs supernatants with and without DV treatment, in the
absence or presence of Akt or ERK inhibitors. In accordance with
our results that Akt inhibitors increased VEGF expression, we also
Figure 1. DV binding to a5b1 is partially mediated through its DGR sequence. (A) Sequence schematic of the second EGF repeat within DV
demonstrating the exact location, highlighted in yellow, where D3904A DV was mutated. (B) Coomassie stain of SDS PAGE of D3904A DV and LG3
protein preparations (left image for each as labeled) and anti-his immunoblot (right image for each as labeled) to recognize the 6xHis-tag present in
the recombinant purified D3904A DV and LG3 (DV C-terminal fragment). In both analyses, D3904A DV yields a single 82 kDa band as does wild-type
DV (not shown), and LG3 yields a single 25 kDa band. (C) Optical biosensor traces showing the association and dissociation of D3904A DV with
immobilized a5b1 integrin at the concentrations listed (RU = relative units). (D) Quantification of proliferation of BECs after 24 h 6 wild-type DV or
D3904A DV at 100 nM or 300 nM concentrations in serum starved media as measured via MTS assay. N = 3, *P,0.05 at 100 nM, P = 0.06 at 300 nM. (E)
Optical biosensor traces showing the association and dissociation of LG3 with immobilized a5b1 integrin at the concentrations listed (RU = relative
units). (F) LG3 (different concentrations of LG3 as labeled) BEC 24 h proliferation assay.
doi:10.1371/journal.pone.0045257.g001
Mechanism of VEGF Section in BECs via Perlecan DV
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observed an increase in VEGF secretion and an additive increase
with the addition of DV (Figure 3C). However, significant
inhibition of DV-induced VEGF secretion was obtained with
10 mM U0126 (Figure 3D), further implicating ERK activation in
DV induced VEGF secretion.
DV Induces VEGF Expression through eIF4E- and c-Jun
Dependent Pathways
VEGF gene expression is highly convergent on the hypoxia-
inducible factor-1 (HIF-1) pathway. While most reports have
investigated HIF-1a under hypoxic conditions, there is a growing
body of evidence that growth factors can activate HIF-1a under
normoxic conditions and cause an increase in VEGF expression
that involves ERK. Because our observations suggest that DV is
signaling through ERK, we hypothesized that the ability of DV to
trigger VEGF expression may also involve activation of HIF-1a in
BECs (Figure 4A). Addition of vehicle alone to BECs did not
induce HIF-1a stabilization. However, DV treatment rapidly
induced HIF-1a stabilization, as we noted its immunopositive
band after 5 min of treatment. This stabilization appeared
transient as HIF-1a immunoreactivity mostly vanished in cells
treated with DV for 30 min.
A possible mechanism by which HIF-1a is stabilized under
normoxic conditions may be via its translation through a
mammalian target of rapamycin (mTOR)-dependent pathway in
which phosphorylation of eukaryotic initiation factor 4E (eIF4E) is
a key step. Therefore, we examined changes in eIF4E phosphor-
ylation (peIF4E) in BECs by western blot (Figure 4B). DV
treatment alone significantly increased detectable peIF4E
(**P,0.01) whereas treatment with LY294002 (10 mM) alone
significantly decreased peIF4E levels compared to untreated
control BECs. The latter result could be due to a minor
contribution of the PI3K/Akt-independent pathway. To confirm
this observation, we measured changes in peIF4E levels in the
Figure 2. DV increases both Akt and ERK phosphorylation. (A) Immunoblots (upper) and OD quantification (lower) for phosphorylated Akt
(pAkt) and pan-Akt (Akt) from BECs in the presence of DV and/or 10 mM LY294002 (PI3K inhibitor). N = 3, *P,0.05 and **P,0.01 versus 0 min
timepoint, ##P,0.01 versus DV-only treated group (vehicle) (B) Immunoblots (upper) and OD quantification (lower) for pAkt and Akt in BECs treated
with 10 mM AktIV (Akt inhibitor). N = 3, *P,0.05 and **P,0.01 versus 0 min timepoint. (C) Immunoblots (upper) and OD quantification (lower) for
phosphorylated ERK (pERK) and pan-ERK (ERK) in BECs treated with 10 mM LY294002. N = 3, **P,0.01 versus 0 min timepoint, #P,0.01 versus DV-
only treated group (vehicle). (D) Immunoblots (upper) and OD quantification (lower) for phosphorylated ERK (pERK) and pan-ERK (ERK) in BECs
treated with 10 mM AktIV. N = 3, **P,0.01 versus 0 min timepoint, #P,0.01 versus DV-only treated group (vehicle).
doi:10.1371/journal.pone.0045257.g002
Mechanism of VEGF Section in BECs via Perlecan DV
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presence of Akt IV inhibitor. Surprisingly, Akt inhibition alone
significantly increased peIF4E levels under basal conditions to
levels similar to DV treatment alone, suggesting a negative effect of
Akt towards the signaling pathway driven by DV. Application of
DV with Akt IV did not further increase peIF4E suggesting that
DV activity or inhibition of Akt activity may be efficient enough to
reach maximum levels of peIF4E levels. Conversely, treatment of
BECs with U0126 (Figure 4C) significantly blocked DV-induced
peIF4E phosphorylation. Lastly, we investigated changes in c-Jun
phosphorylation, a protein belonging to the AP-1 complex that
induces VEGF through an ERK-dependent mechanism
(Figure 4D). DV treatment significantly increased phospho-c-Jun
at 30 min that was significantly blocked by U0126.
DV-induced VEGF Secretion Induces Functional Changes
in Angiogenesis in BECs in vitro
VEGF constitutes an important factor eliciting endothelial cell
tube formation, permeability [26], and proliferation [27,28].
Therefore, we investigated changes in these biological features
as a direct readout of DV activity. First, to more closely mimic
the brain microenvironment in vitro, we developed an endothe-
lial cell-neuron co-culture capillary tube-like structure formation
assay. In this assay, BECs or mouse dermal microvascular
endothelial cells (DECs) were cultured on a bed of rat granule
neurons (Figure 5A, B). Under control conditions, BEC’s
segregated from neurons and did not form capillary tube-like
structures. However, BECs did form capillary tube-like struc-
tures within 6 hours of direct VEGF treatment, as expected, or
DV treatment. VEGF and DV effects could be inhibited by
VEGF neutralizing antibody. Similarly, DECs formed capillary
tube-like structures when treated with VEGF, but became more
segregated from neurons than under control conditions, where
cells did not form tube-like structures, but were more
distributed/dispersed among the neurons. In these cells DV
treatment also mimicked the effects of direct VEGF treatment.
Furthermore, the formation of endothelial tube-like structures
was dependent upon the presence of granule neurons. Indeed,
in the absence of granule neurons, but with granule neuron-
conditioned media, neither VEGF nor DV treated BECs could
form tube-like structures [29] (data not shown).
In addition to changes in tube formation, DV promoted BEC
proliferation (Figure 5C), which could be blocked with SU1498, an
inhibitor of VEGF receptor 2, suggesting that DV’s proliferative
effect is also driven through a VEGF-dependent mechanism.
Finally, treatment with U0126 also inhibited DV-induced
increased proliferation (Figure 5D) denoting the role played by
the ERK signaling pathway in DV’s effects on BECs.
Figure 3. DV increases VEGF-A at mRNA and protein level through an ERK-dependent pathway. (A) qPCR analysis of VEGF-A mRNA in
BECs +/2 DV and +/210 mM LY294002 or 10 mM AktIV. GAPDH was used as internal control. N = 3, ***P,0.001 in comparison between DV-treated
and untreated cells, ##P,0.01 in comparison between inhibitors and untreated groups. (B) Similar analysis as in (A) demonstrating that 10 mM U0126
(MEK inhibitor) treatment significantly blunted DV-induced VEGF-A mRNA up-regulation. N = 3. ***P,0.001 in comparison between DV-treated and
untreated cells. (C) Secreted VEGF ELISA profile from BECs following treatment with DV, LY294002, or AktIV alone or in combination Note the
significant up-regulation of secreted VEGF following DV, LY294002 or AktIV treatment. N = 3, ***P,0.001 in comparison between DV-treated and
untreated cells, ##P,0.01 in comparison between LY and AktIV treated groups versus untreated group. (D) U0126 treatment significantly inhibited
VEGF secretion from BECs following DV treatment. N = 3. ***P,0.001 in comparison between DV-treated and untreated cells.
doi:10.1371/journal.pone.0045257.g003
Mechanism of VEGF Section in BECs via Perlecan DV
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Discussion
Identifying enhancers of endogenous post-stroke brain repair
may result in novel stroke therapies. Among the potential brain
repair enhancers, VEGF is particularly interesting because of its
functional roles in post-stroke neuroprotection, neurogenesis and
angiogenesis [30–32]. However, direct administration of VEGF
acutely after stroke has failed as a therapy, or even worsened stroke
damage, largely due to its hyperpermeability effect on the blood-
brain barrier [33–35]. Indeed, VEGF stroke therapy can be
considered to be a ‘‘double-edged sword’’, inasmuch as acute
treatment results in blood-brain barrier breakdown, whereas
delayed treatment promotes neuroprotection and repair. There-
fore, finding the appropriate therapeutic window in a time- and
concentration-dependent manner is essential for considering
therapies associated with VEGF. In this study, we investigated
the cellular mechanisms by which DV, a bioactive ECM fragment
released after stroke [14] leads to VEGF secretion and eventually
Figure 4. DV induces HIF-1a and increases eukaryotic initiation factor 4E. (A) HIF-1a immunoblot (upper) and OD quantification (lower)
following DV exposure. Note the transient HIF-1a band at 5 minutes. N = 3, *P,0.05, **P,0.01 and ***P,0.001 in comparison between vehicle and
DV treated cells. (B) Immunoblots (upper) of eukaryotic initiation factor 4E phosphorylation (peIF4E) and total eIF4E after treatment of BECs with
combinations of DV, LY294002 and AktIV as labeled. Cells were treated with DV for 5 min. OD quantification (lower) of peIF4E as normalized to total
eIF4E. N = 3, **P,0.01 versus untreated cells, ##P,0.01 within LY294002 treated-group (C) Immunoblots (upper) of peIF4E and eIF4E from BECs
treated with combinations of DV and U0126 as labeled demonstrating that U0126 significantly abolished DV-induced peIF4E hyperphosphorylation
as OD quantified (lower). Cells were treated with DV for 5 min. N = 3, **P,0.01 versus control, ##P,0.01 versus DV-treated group. (D) Immunoblots
(upper) of phosphorylated c-jun (pc-jun) and total c-jun from BECs treated with DV +/2 U0126 demonstrating that U0126 significantly inhibited DV-
induced c-Jun phosphorylation as OD quantified (lower). Note the significant increase after 30 min following DV treatment. N = 3, **P,0.01 in
comparison to untreated cells, ##P,0.01 between U0126-treated and untreated cells.
doi:10.1371/journal.pone.0045257.g004
Mechanism of VEGF Section in BECs via Perlecan DV
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to its neuroprotective and pro-angiogenic effects [14], as
schematized in Figure 6.
DV Binding to a5b1 Integrin
Interestingly, DV has demonstrated two opposing effects on
angiogenesis explained mostly by an integrin-dependent mecha-
nism: a peripheral anti-angiogenic effect (leading to DV’s other
name, endorepellin) driven by a2b1 [11], and a brain pro-
angiogenic effect driven by a5b1 [14]. In this study, we examined a
novel signaling pathway in which DV increases VEGF expression
and secretion from BECs. We also further investigated the
interaction between DV and the a5b1 integrin as well as its
importance to DV’s pro-angiogenic effect. We hypothesized that
DV’s interaction with a5b1 may occur, at least in part, through
DV’s DGR sequence located at the amino acid position 3904
within the EGF2 repeat. The DGR sequence is known to
isomerize to an iso-DGR sequence and become a competitive
antagonist for RGD ligands [36]. Other studies claim that the iso-
DGR sequence is not required for fibronectin binding to a5b1
[37]. Here, we demonstrated that mutation of DV’s DGR
sequence to AGR resulted in a significant decrease in a5b1
binding and in BEC proliferation, suggesting that the DGR
sequence contributes to DV-a5b1 interaction, but not that DGR is
solely responsible for this binding.
Next, as previous reports demonstrated that most of DV’s a2b1
integrin-mediated anti-angiogenic activity outside of the brain was
driven via its C-terminal LG3 subdomain, despite LG3 having
lower affinity than DV for a2b1 integrin [11,16,38], we
investigated LG3’s ability to bind to a5b1 integrin and influence
BEC proliferation. Similar to LG3’s lower affinity for a2b1, we
noted a low, micromolar range Kd for LG3 binding to a5b1
integrin. However, unlike previous studies demonstrating that
lower nanomolar concentrations of LG3 were as or more effective
than DV in inhibiting angiogenesis in nonbrain endothelial cells,
LG3 was less effective in enhancing angiogenesis (i.e. BEC
proliferation) than DV. This seeming contradiction in LG3’s
relative potency for anti- versus pro- angiogenic effects, despite
similarly low affinities for the implicated DV b1 integrin receptor,
underscores potential differences in LG3 anti- and pro-angiogenic
signaling. Importantly, in our previous work, we noted that LG3
was anti-angiogenic in the human brain endothelial cell line
hCMEC/D3 [15]. At that time we speculated that this might be
due to differences in LG3’s affinity for a5b1 integrin. However, we
have since determined (Figure S1) that hCMEC/D3 cells
surprisingly (and atypically for the majority of microvascular
brain endothelial cells) express DV’s anti-angiogenic a2b1 recep-
tor. As we have previously demonstrated that DV is anti-
angiogenic in BECs that normally do not express the a2b1 via
a2 integrin plasmid transfection [14], the presence of the a2b1
Figure 5. DV enhances brain endothelial cell capillary tube-like structure formation in neuronal co-culture in a VEGF-dependent
fashion. (A) BECs or mouse dermal endothelial cells (DECs, red) were cultured on a bed of rat cerebellar granule neurons (green) in serum free
medium for 6 hours +/2 PBS vehicle control, VEGF, DV, or DV+VEGF neutralizing antibody. Scale bar is 50 mm. (B) Quantification of capillary tube-like
structures as in A. *P,0.05 compared to corresponding control. (C) and (D) Quantification of percent BEC proliferation after 24 h (in reference to
control, PBS vehicle treated condition arbitrarily set at 100%) treated as labeled. ***P,0.001.
doi:10.1371/journal.pone.0045257.g005
Mechanism of VEGF Section in BECs via Perlecan DV
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integrin in the hCMEC/D3 cell line is likely what accounts for
LG3’s previously noted anti-angiogenic effect in these cells.
Collectively, this study suggests that DV’s DGR binding motif
plays an important role in DV binding to a5b1 and hints at a more
complex role for DV’s LG3 subcomponent in DV’s pro-
angiogenic effects.
DV Signal Transduction in BECs
In this study, we demonstrate that DV’s activation of ERK-
dependent signaling pathways is the primary player in inducing
VEGF expression in BECs. Erythropoietin, another important
neuroprotective growth factor [39], has also been demonstrated to
increase secretion of VEGF by activating Akt- and ERK-
Figure 6. Schematic representation of DV signal transduction, VEGF gene expression, secretion and its subsequent activity at the
neurovascular unit. Proposed model by which DV interaction with the BEC a5b1 integrin results in increased VEGF production and secretion. The
use of various antagonists (red lines) is also shown.
doi:10.1371/journal.pone.0045257.g006
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dependent pathways. [30], Therefore, the ERK pathway may
represent a convergence point for induction of VEGF upregula-
tion. Interestingly, inhibitory crosstalk from Akt to ERK pathways
has been previously reported [25]. Our work demonstrates that
inhibition of Akt enhances rather than blocks DV’s induction of
VEGF, whereas inhibition of ERK completely abolishes DV’s
upregulation of VEGF at both the mRNA and protein levels. This
suggests that the majority of DV induction of VEGF is through
ERK dependent pathways subject to negative regulation control
mediated through Akt. These opposing pathways may be partially
reconciled by preliminary studies in our laboratory where we
observed a significant increase in pAkt, peIF4E and HIF-1a levels
under basal conditions in a5 knockdown cells, whereas pERK was
significantly decreased. These results suggest that a5b1 integrin
conveys a basal ERK-dependent activity that directly or indirectly
inhibits an Akt-dependent pathway.
In addition to the activation of these pathways, we demonstrat-
ed the ability of DV to transiently stabilize HIF-1a in a normoxic
environment. Stabilization of HIF-1a through an O22indepen-
dent mechanism has been previously described as being mostly
driven by activation of the mTOR signaling pathway following
Akt phosphorylation [40,41], which is caused by a globalized
increased protein translation in general and of HIF-1a in
particular. In additional preliminary studies, we noted an
intriguing stabilization of HIF-1a in a5b1-knockdown cells. Until
now, no studies have directly investigated the reason for such
stabilization, although a recent study carried out by Ryu and
colleagues [42] demonstrated the ability of HIF-1a to up-regulate
fibronectin and its cognate receptor, a5b1 integrin, suggesting a
certain relationship between a5b1 and HIF-1a that will be
addressed in more detail in future studies.
This study further highlights the essential role of the a5b1
integrin for DV signal transduction, and DV’s induction of VEGF
in BECs. In addition to an increase of VEGF through an HIF-1a
dependent mechanism, we observed c-Jun phosphorylation
following DV exposure. This is in agreement with previous
literature that demonstrated a direct correlation between increased
c-Jun phosphorylation and VEGF expression [43]. Interestingly,
other studies have demonstrated a positive cooperative role
between HIF-1a and c-Jun [44,45] suggesting the possibility of a
synergistic effect between these two pathways. Specifically, these
studies indicate that expression of VEGF through an ERK-
dependent pathway, as observed in our study, is strongly amplified
by concurrent activation of both HIF-1a dependent and
independent (c-Jun) pathways. These findings reinforce the
relevance of the signaling pathway detailed here as the main
route by which the DV signal is transduced to VEGF production.
DV and VEGF-mediated Effects on Brain Endothelial Cells
In this study, we demonstrated the relevance of DV-induced
VEGF secretion through its biological activity on BECs. We
primarily assessed the biological relevance of DV-induced VEGF
secretion by investigating changes in endothelial cell proliferation
and tube-like structure formation, two important cellular behav-
iors essential for angiogenesis. We demonstrated in a novel
endothelial cell-neuron capillary morphogenesis assay that, con-
sistent with our previous results [14], DV enhances BEC capillary
morphogenesis in a VEGF dependent fashion, while inhibiting
non-brain capillary morphogenesis as expected. While the
possibility that DV influences BEC cell capillary morphogenesis
via effects on the neurons present in the assay cannot be ruled out
in this co-culture system, it is important to note that preliminary
ELISA studies with DV treated neurons did not show increased
levels of secreted pro-angiogenic factors including VEGF, BDNF,
and NGF (data not shown) suggesting that DV-induced neuronal
release of these factors is not a likely cause of DV-enhanced BEC
capillary morphogenesis. Likewise, as neither VEGF or DV could
induce capillary tube morphogenesis when the granule cells were
removed in such a way that their secreted matrix and growth
factors remained, the neurons themselves may provide a physical
scaffold or platform for intercellular crosstalk for capillary
formation under the appropriate circumstances (i.e. in the
presence of pro-angiogenic factors such as VEGF or DV). Stated
differently, DV, by increasing BEC production and release of
VEGF, may foster direct and crosstalk interactions between BECs
and neurons that leads to increased angiogenesis. However, it is
also important to note that adding endothelial cells to neurons
most likely results in changes to the extracellular matrix secreted
by the neurons and/or the endothelial cells, which could then in
turn contribute to DV’s effects on endothelial cell capillary
morphogenesis in the co-culture environment.
In conclusion, we propose the following context for DV action
as a novel stroke treatment - Perlecan undergoes proteolysis
following cerebral ischemia due to the cellular release of various
proteases [4]. Simultaneously, there is an integrin ‘‘switch’’ in
brain microvascular endothelial cells from a quiescent state to a
pro-angiogenic state that involves an increase in their expression of
the pro-angiogenic a5b1 integrin (and a decrease in the expression
of a6b1 integrin) following hypoxia [5]. Our previous results [14]
demonstrate that DV both contributes to the increase in brain
microvascular endothelial cell a5b1 integrin expression and
directly interacts with the a5b1 integrin, leading to increased
production and release of VEGF. VEGF then plays an important
role in DV’s neuroprotective and pro-angiogenic effects following
experimental brain stroke in rodents. In the current study, we
expanded on previous findings by detailing how DV interacts with
the a5b1integrin, which occurs at least in part, via DV’s DGR
amino acid sequence. Finally, we have identified the signaling
cascade(s), involved with DV’s induction of VEGF release and
linked them with functional significance in brain endothelial cells
shedding further light on DV’s potential VEGF-mediated ischemic
stroke therapeutic mechanism of action.
Materials and Methods
Ethics Statement
N/A.
Cell Culture
Brain microvascular endothelial cells (BECs) from C57Bl6 mice
were kindly provided by Dr. Jane Welsh (Texas A&M University)
[46] [14]. Cells were grown on gelatin-coated dishes in the
presence of Iscove’s Modified Dulbecco’s Medium (IMDM,
Invitrogen, Carlsbad, CA) supplemented with 10% Fetal Bovine
Serum (FBS, heat inactivated used in all protocols, Sigma-Aldrich,
St. Louis, MO) and 1% antibiotic/antimycotic solution (Cellgro,
Mediatech Inc, Manassas, VA).
Recombinant DV Synthesis and Purification
Human recombinant DV was cloned and purified following
established protocols [14]. The 26-kDa LG3 C-terminal domain of
DV was cloned (Table S1), ligated using the pCep-Pu vector and
expressed in HEK-293EBNA cells. LG3 was purified and assessed
for purity using similar methods from our previous publication
[14]. Mutation of DV at its DGR site (D3904A DV) was done
using the Quikchange II XL Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) and confirmed by
sequencing. The mutated DV protein was then produced, purified
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and assessed for purity using Coomassie Brilliant Blue stained SDS
PAGE as previously reported [14].
DV and a5b1 Integrin Interaction Assays
Binding of DV to a5b1 integrin was assessed by interaction assay
system biosensor (IAsys, Affinity Sensors, UK) following previously
described protocols with immobilized a5b1 integrin (kindly
provided by Martin Humphries, U. Manchester)[14], [47]. Free
LG3 was added at concentrations ranging from 3.161028 M to
3.161027 M and D3904A DV at concentrations ranging from
8.061028 M to 4.061027 M. Data from the biosensor were
analyzed by the global fitting method described by Myszka and
Morton [48]. For each assay, the association rate constants (kon)
and the dissociation rate constants (koff) were obtained, and the
equilibrium dissociation constants (Kd) values were calculated from
a ratio of koff/kon. In addition, control binding of bovine serum
albumin (BSA) at the molar concentration of 8.061027 (double of
the highest concentration for DV) was also performed.
Immunoblots
Medium containing 10% FBS was removed from confluent
BECs, which were then quickly rinsed one time with pre-warmed
(37uC) PBS. The PBS was then quickly removed and replaced with
fresh pre-warmed (37uC) medium containing 1% FBS. The cells
were serum-starved for 24 h in this 1% FBS containing medium.
After 24 hours, this medium was removed and replaced with fresh,
pre-warmed (37uC) 1% FBS containing medium. Following two
hours of incubation, DV (20 mg/mL) was added directly to the
plates (avoiding as much agitation as possible to not induce any
artificial signaling) for varying time points at 37uC and 5% CO2.
For inhibition experiments the same precautions were followed
prior to pretreatment of cells for 1 h in the presence of inhibitors at
the manufacturer’s recommended doses of 10 mM LY294002 (Cell
Signaling Technology, Danvers, MA), 10 mM U0126 (Cell
Signaling Technology) or 10 mM AktIV inhibitor (Calbiochem,
EMD Chemicals, San Diego, CA), followed by DV treatment. The
final concentration of DMSO never exceeded 0.1%.
BECs were washed with ice-cold PBS, homogenized in RIPA
lysis buffer (Cell Signaling Technology) complemented with
protease inhibitor cocktail (Calbiochem) and centrifuged 10
minutes at 14,000 rpm. Lysate protein concentration was assessed
by BCA (Thermo Scientific, Rockford, IL). Samples (20 mg/lane)
were loaded onto a 10% SDS-PAGE gel and subsequently
transferred to PVDF membranes. Membranes were blocked in 5%
non-fat dry milk followed by an overnight incubation at 4uC in the
presence of antibodies directed against phospho-Akt (Cell Signal-
ing), pan-Akt (Cell Signaling Technology), phospho-ERK1/2
(R&D Systems, Minneapolis, MN), pan-ERK1/2 (R&D Systems),
phospho-eIF4E (Cell Signaling Technology), eIF4E (Cell Signaling
Technology), HIF-1a (Novus Biological, Littleton, CA) or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Sigma-Al-
drich). Membranes were washed with TBS-0.1% Tween-20 and
incubated in presence of horseradish peroxidase (HRP) conjugated
secondary antibody (Genetex, Irvine, CA). Band detection was
performed by enhanced chemiluminescent substrate (Picowest
Signal, Thermo-Fisher Scientific) and captured by X-ray films.
Blot optical density quantification was performed using ImageJ
software (ImageJ, NIH, Bethesda, MD). For ERK and pERK,
doublet band optical densities for each were added together for
quantification.
qPCR Gene Expression
BECs were washed with ice-cold PBS and total RNA was
extracted following 1.5 h DV treatment using RNeasy MiniKit
(Qiagen, Valencia, CA). Total RNA was quantified by UV
spectrophotomer (Beckman-Coulter, Brea, CA). cDNA were
obtained from 1 mg total RNA using AMV reverse transcriptase
(Invitrogen). qPCR was performed using TaqManH Fast Universal
PCR Kit (Applied Biosystems, Carlsbad, CA) and appropriate
probes (Table S1). DCT and DDCT values were calculated using
Applied Biosystems 7500 Fast Reverse transcriptase PCR software
(Applied Biosystems). GAPDH served as internal control for
normalization.
VEGF ELISA Assay
BECs were serum-starved in 1% FBS containing medium as
described above for 24 hours, and then incubated with fresh 1%
serum-containing media containing various DV concentrations.
Conditioned-medium was collected and spun down at 10,000 g for
5 minutes. VEGF in the conditioned medium was detected using
VEGF ELISA kits (Ray Biotech Inc., Norcross, GA) following the
manufacturer’s instructions.
Proliferation Assay
BECs were seeded in 96-well plates at a concentration of 4,000
cells/well in IMDM medium containing 10% FBS. Following
overnight incubation, BECs were washed with warm PBS and
incubated in serum-free medium (1% FBS) in the presence or
absence of 20 mg/mL DV +/2 various inhibitors for an additional
24 hours. Following this incubation, 3-(4, 5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium so-
lution (MTS, CellTiter 96 Aqueous, Promega, Madison, WI) was
added to each well for an additional two hours at 37uC and 5%
CO2. Changes in MTS coloration were assessed at 490 nm using
an absorbance plate reader (Sunrise Phoenix, Tecan, Maennedorf,
Switzerland).
Neuron-endothelial Cell co-culture Tubulogenesis Assay
Cerebellar granule neurons were isolated from the cerebellum
of postnatal day 8 rats as previously published [49] generating a
.95% pure population. The neurons were then added to an 8
chamber well slide (56104 cells/well) pre-coated with laminin
(Invitrogen) and allowed to grow overnight in Dulbecco’s Modified
Eagle Medium (DMEM) containing 10% FBS, 10% horse serum,
glucose (6 mM), insulin (10 mg/mL), glutamine (200 mM). The
following day, BECs or primary mouse dermal microvascular
endothelial cells (DECs, Celprogen, San Pedro, CA) were added to
the neuron containing wells (36104 cells/well) and allowed to
grow overnight in DMEM containing serum. Next, cells were
vigorously washed with warm PBS to remove serum and further
incubated in serum-free DMEM containing 20 mg/mL DV in the
presence or absence of VEGF neutralizing antibodies for up to
6 h. VEGF-treated cells were used as positive controls. In some
experiments, prior to the addition of the endothelial cells, the
neurons were removed following previously published protocols
[29] such that their secreted ECM and attached growth factors
remained. In other experiments, endothelial cells were added to
laminin-coated wells overnight, followed by treatment with VEGF,
DV or DV+VEGF neutralizing antibody in cerebellar granule cell
conditioned media.
Cells were fixed with 4% paraformaldehyde solution (w/v),
permeabilized with 0.1% Triton-X100 and incubated in primary
antibodies raised against von Willebrand factor (Dako Cytoma-
tion, Denmark) or Tuj-1 (Neuromics, Edina, MN). Cells were
washed and further incubated in fluorochrome-conjugated
secondary antibodies (Jackson ImmunoResearch, West Grove,
PA). Cells were visualized on a confocal microscope (Zeiss, New
York, NY). Tube formation was quantified as pixels per high-
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power field, using Photoshop CS (Adobe, San Jose, CA). Tube
formation were measured from 10 random fields per treatment
condition, with each treatment condition performed in triplicate
per experiment, and three independent experiments performed.
Statistical Analysis
Data are presented as Mean6SD from a minimum of three
independent experiments. Statistical tests were performed using
one-way and two-way ANOVA analysis function in Graphpad
Prism 4.0 (Graphpad Software, La Jolla, CA). P,0.05 was
considered to be statistically significant.
Supporting Information
Figure S1 Differential expression of a2 integrin in
hCMEC/D3 and C57BL6 BEC cells. Anti-a2 integrin
(160 kDa) western blot on hCMEC/D3 cells and BECs from
C57Bl6 mice, with GAPDH protein (38 kDa) loading control,
demonstrating the presence and absence, respectively, of this
integrin in these two cell types.
(TIF)
Table S1 Sequences used for the generation of recom-
binant proteins and quantitative PCR analysis. Forward
and reverse sequence primers used in this study to generate
D3904A mutated domain V (upper lines); PCR primers accession
numbers used for the quantification VEGF-A and GAPDH gene
expression (lower lines).
(TIF)
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